Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

55.20
-1.0200-1.81%
Post-market: 55.200.00000.00%16:15 EDT
Volume:2.08M
Turnover:114.87M
Market Cap:10.67B
PE:145.65
High:56.60
Open:56.05
Low:54.76
Close:56.22
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.85
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.69
PE(LYR):30.67

Loading ...

BioMarin Expects Alesta Acquisition to Cut Full-Year 2026 GAAP, Non-GAAP Diluted EPS by About $1.55

Reuters
·
Yesterday

Biomarin Pharmaceutical - Expects $1.5 Unfavorable Impact to Gaap and Non-Gaap Diluted EPS for Q3 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

Biomarin Pharmaceutical - Expects Q3 2026 Pre-Tax Charges of $283 Mln for Bought Ipr&D Expense - SEC Filing

THOMSON REUTERS
·
Yesterday

Biomarin Appoints Cara Bauer as Chief People Officer

THOMSON REUTERS
·
Oct 06

Press Release: BioMarin Appoints Cara Bauer as Chief People Officer

Dow Jones
·
Oct 06

BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA

TIPRANKS
·
Oct 02

BioMarin Reports Five-Year Phase 3 Propel Extension Data for Pombiliti Plus Opfolda in Late-Onset Pompe Disease

Reuters
·
Oct 02

BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration

Simply Wall St.
·
Oct 01

Biomarin Pharmaceutical Enters Settlement and License Agreement with Ascendis Pharma on Sept 24, 2026

Reuters
·
Oct 01

Biomarin Pharmaceutical - Co and Ascendis to Dismiss All Pending Litigation with Prejudice - SEC Filing

THOMSON REUTERS
·
Oct 01

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% US, 18% EU/Br/SK Royalty on Sales Until May 2030 - SEC Filing

THOMSON REUTERS
·
Oct 01

Biomarin Pharmaceutical - Grants Ascendis License for Transcon Cnp, Navepegritide, Yuviwel - SEC Filing

THOMSON REUTERS
·
Oct 01

BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products

Reuters
·
Oct 01

Travere Therapeutics Names Bradley Campbell CEO, Effective Dec. 1, 2026

Reuters
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Biomarin Pharmaceutical Inc. : JP Morgan Raises Target Price to $86 from $80

THOMSON REUTERS
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17

BioMarin price target lowered to $97 from $98 at BMO Capital

TIPRANKS
·
Sep 15

BioMarin to discontinue development of Voxzogo for children with Noonan syndrome

TIPRANKS
·
Sep 15

Biomarin Pharmaceutical - Discontinues Development of Voxzogo for Children with Noonan Syndrome on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 15